Media Resources

Living Cell Technologies Receives A$6.0M in Capital Placement

November 30, 2007 - Melbourne, Australia and Auckland, New Zealand - Living Cell Technologies Limited (ASX:LCT; OTC: LVCLY.PK) today announced that it has received A$6.0 million in funds for the capital placement announced on October 30. Shareholders have subscribed for the issue of 20,000, 000 ordinary shares at A$0.30 per share. This Taylor Collison Limited placement of A $6.0 million follows the closing of a placement of US$2 million by U.S.-based NaviGroup Management Ltd on November 6, 2007

Living Cell Technologies Updates Shareholders on Clinical Trial Progress at Annual General Meeting

November 27, 2007 - Melbourne, Australia and Auckland, New Zealand - Living Cell Technologies Limited (ASX:LCT; OTC: LVCLY.PK) today updated shareholders at its Annual General Meeting on the Company’s Russian clinical trial, the status of its New Zealand clinical trial and commercialisation plans.

Investor Newsletter 2007

LCT announces $6.4m capital placement following positive clinical data

30 October 2007 - Auckland, New Zealand and Melbourne, Australia: Living Cell Technologies Ltd (ASX:LCT, OTC: LVCLY) announces that it has closed a further private placement bringing a total of $6.4million in additional share capital to the company.

Further Positive Preliminary Data on DIABECELL® Phase I/IIa Trial

22 October 2007 - Auckland, New Zealand and Melbourne, Australia: Living Cell Technologies Ltd (ASX:LCT, OTC: LVCLY) is releasing this update on the excellent initial responses observed in its DIABECELL® trial in Russia to ensure that the information is available to all shareholders, following the preliminary announcement on October 9th.

Positive Preliminary Data on
DIABECELL® Phase I/IIa Trial

9 October 2007 - Auckland, New Zealand and Melbourne, Australia:
Living Cell Technologies Ltd (ASX:LCT, OTC: LVCLY) is releasing this announcement concerning positive results of its Russian diabetes transplant trial to ensure that clinical information is available to all shareholders.

LCT Receives Approval for DIABECELL®
Clinical Trial in NZ

12 September 2007 - Auckland, New Zealand and Melbourne, Australia:
Key Points:

• LCT receives Regional Ethics Committee approval for diabetes clinical trial in NZ
• LCT pig cell transplant diabetes phase I/IIa trial on track to start by end of 2007
• LCT is the only company world-wide to obtain clinical trial approval for a pig cell transplant without immunosuppression under current regulatory guidelines
• DIABECELL® product targets the type 1 diabetes market – with 24 million sufferers globally

Living Cell Technologies Featured on ABCTV Program, 7.30 Report

29 August 2007 - New Zealand, Australia: World leading xeno cell therapy company, Living Cell Technologies (ASX:LCT; US OTC: LVCLY) announced today that it will be featured on the ABC television network current affairs program, The 7.30 Report at 7.30 pm Wednesday 29 August 2007.

LCT appoints David Brookes as independent Director to the Board

23 August 2007 - ASX Announcement – Melbourne, Australia:
Living Cell Technologies Limited (ASX:LCT, OTC: LVCLY) today announced the appointment of Dr. David Brookes, as an independent Director to the Board.

Quarterly Cash Flow Report Period Ended
30 June 2007

31 July 2007 - ASX Announcement – Attached is the Appendix 4C – Quarterly Cash Flow Report – for Living Cell Technologies (ASX:LCT, OTC:LVCLY) for the quarter ended 30 June 2007.

Living Cell Technologies awarded NZ$100,000
from NZ Government

5 July, 2007 - Melbourne, Australia and Auckland, New Zealand: Living Cell Technologies Limited (ASX: LCT) today announced that it has been awarded an Enterprise Development Grant of NZ$100,000 from New Zealand Trade & Enterprise to assist the Company’s market development activities internationally.

Diabetes Patient Successfully Transplanted in
World-first DIABECELL® Trial

14 June, 2007 - Melbourne, Australia and Auckland, New Zealand:
Key Points:

• First type I diabetes patient was successfully dosed with DIABECELL® pig cell implant
• DIABECELL® therapy is aimed at controlling the dangerous blood glucose levels and longterm secondary complications affecting people with type I diabetes
• LCT is conducting the clinical trial according to stringent international regulatory Guidelines

Diabetes Patient Successfully Transplanted in
World-first DIABECELL® Trial

22 May 2007 - Melbourne, Australia and Auckland, New Zealand:
Key Points:

• LCT awarded world-first IANZ accreditation for xenotransplantation laboratory
• Major step toward commencing DIABECELL® clinical trials in New Zealand in 2007
• Xenotransplant laboratory is accredited to test and monitor for a range of animal & human viruses and its lab reports will be accepted by forty-nine countries including: the US, UK. and Canada.

Newsletter May 07

Quarterly Cash Flow Report Period Ended
31 March 2007

30 April 2007 - ASX Announcement - Attached is the Appendix 4C – Quarterly Cash Flow Report – for Living Cell Technologies (ASX:LCT)
for the quarter ended 31 March 2007.

Regulatory Review allows LCT Diabetes Clinical Program to Proceed

17 April 2007 - Auckland, New Zealand and Melbourne, Australia: Living Cell Technologies Ltd (ASX:LCT) after rigorous international review has received authorization from the New Zealand regulator MedSafe to advance its program to conduct a Phase I/IIa clinical trial of its DIABECELL® diabetes product in New Zealand.

LCT Reports Major Step Forward for Islet Transplantation in Diabetes Patient

30 March, 2007 - Melbourne, Australia: Living Cell Technologies Limited (ASX: LCT) today announced that it will establish a Level 1 American Depositary Receipt Program (ADR), appointing The Bank of New York as its depository bank. The establishment of an ADR program in the United States is intended to facilitate trading in LCT shares by US investors.

LCT Half Yearly Report Period Ended
31 December 2006

28 February 2007 - Melbourne, Australia: Attached is the Appendix 4D – Half Yearly Report – for Living Cell Technologies (ASX:LCT) for the six month period ended 31 December 2006, as well as an overview of the significant improvement in cash position since year end.

31_01_07 Taylor Collison Report

LCT to start clinical trial of Type 1
diabetes treatment

30 January 2007 - Melbourne, Australia and Auckland, New Zealand: Living Cell Technologies Ltd (ASX:LCT) today announced its DIABECELL® Type 1 diabetes treatment has been approved for a Phase I/IIA clinical trial in Russia designed according to FDA guidelines and monitored by a Boston-based Contract Research Organisation.